Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Opole
Clinical trial register · Poland

Clinical Trials in Opole, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Poland and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2716 matching records held by the registry are in this view. Synced 15 Nov 2026, 03:18 UTC
2716
Studies in scope
all four open statuses
1383
Recruiting now
open to new participants
510
Lead sponsors
across recruiting studies
Top sites
Warsaw 1322 Krakow 882 Poznan 697 Gdansk 665 Lodz 621
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC8 Eli Lilly and Company7 Bristol-Myers Squibb7 AstraZeneca7 Pfizer5 Hoffmann-La Roche4 Spyre Therapeutics, Inc.3 Takeda3 BeOne Medicines3 Gilead Sciences2 Alleviant Medical, Inc.2 Novartis Pharmaceuticals2 Celcuity Inc2 Acerta Pharma BV2 Merck Sharp & Dohme LLC2 Sanofi2 Greenwich LifeSciences, Inc.1 Sellas Life Sciences Group1 Celldex Therapeutics1 UNICANCER1 Syndax Pharmaceuticals1 Vanda Pharmaceuticals1 Heidelberg Pharma AG1 PolTREG S.A.1 Windtree Therapeutics1 Show all 61
Site location
Warsaw1322 Krakow882 Poznan697 Gdansk665 Lodz621 Wroclaw528 Lublin527 Bydgoszcz525 Katowice511 Bialystok389 Olsztyn192 Szczecin182 Rzeszów182 Gdynia168 Gliwice121 Kielce117 Torun110 Opole106 Koszalin83 Siedlce81 Zabrze71 Elblag67 Otwock56 Przemyśl55 Chorzów54 Show all 262
All 262 locations
Target enrolment
to

Trials with a site in Opole

106 of 2716 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Poland
Start
Not yet open
Wockhardt
Phase 3
324
Lublin, Opole, Krakow, Zabrze
2026-10-28
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
Skórzewo, Krakow, Wroclaw, Otwock, Siedlce, Warsaw, Opole, Przemyśl
2026-09-11
Recruiting
Takeda
Observational
110
Poznan, Bydgoszcz, Krakow, Lublin, Warsaw, Opole, Przemyśl, Bialystok
2026-08-13
Recruiting
Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests
NCT07106632Early Breast Cancer, Premenopausal Breast Cancer, HR+/HER2- Breast Cancer
UNICANCER
Phase 3
3,380
Gdansk, Gliwice, Lodz, Opole, Poznan, Szczecin, Warsaw
2026-06-26
By invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Bydgoszcz, Krakow, Kłodzko, Lodz, Opole, Poznan, Rzeszów, Sopot
2026-06-08
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Bydgoszcz, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin, Torun
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bydgoszcz, Chorzów, Krakow, Lublin, Olsztyn, Opole, Rzeszów, Szczecin
2026-05-22
Recruiting
BeOne Medicines
Phase 3
1,056
Bialystok, Gdynia, Kielce, Krakow, Opole, Otwock, Warsaw
2026-05-22
Recruiting
Hoffmann-La Roche
Phase 2/3
650
?ód?, Katowice, Krakow, Olsztyn, Opole, Późna, Tomaszów Mazowiecki, Wroc?aw
2026-05-21
Recruiting
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07146906Immunoglobulin A Nephropathy (IgAN)
DrugZigakibart
Novartis Pharmaceuticals
Phase 2
32
Lodz, Opole
2026-03-26
Recruiting
Yuhan Corporation
Phase 2
150
Poznan, Krakow, Tarnów, Wroclaw, Lublin, Opole, Bialystok, Katowice
2026-03-26
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Bialystok, Bydgoszcz, Gdynia, Krakow, Lublin, Opole, Tarnów, Tychy
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 3
850
Lublin, Opole, Przemyśl, Katowice
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Warsaw, Opole, Jelenia Góra
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Opole, Przemyśl, Katowice, Lodz
2026-03-12
Recruiting
Astellas Pharma Global Development, Inc.
Phase 2
240
Lodz, Opole, Poznan, Przemyśl
2026-03-12
Recruiting
Takeda
Phase 3
1,182
Bialystok, Bytom, Dąbrówka, Krakow, Lodz, Nowa Sól, Olsztyn, Opole
2026-03-11
Recruiting
Sanofi
Phase 3
751
Bydgoszcz, Elblag, Katowice, Krakow, Kłodzko, Lublin, Opole, Poznan
2026-01-16
Recruiting
Celldex Therapeutics
Phase 3
240
Gdansk, Krakow, Lodz, Lublin, Opole, Oświęcim, Rzeszów, Tarnów
2026-01-15
Recruiting
Novo Nordisk A/S
Phase 3
460
Dziekanów Leśny, Opole, Rzeszów, Zabrze
2026-01-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Radom, Katowice, Kielce, Lodz, Lublin, Opole, Wroclaw, Tomaszów Mazowiecki
2026-01-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Krakow, Warsaw, Wieliszew, Opole, Brzozów, Gdansk, Gliwice, Koszalin
2025-12-31
Recruiting
Pfizer
Phase 3
800
Katowice, Koszalin, Krakow, Opole, Poznan
2025-12-11
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Wałbrzych, Opole, Olsztyn
2025-11-25
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Opole, Poznan, Warsaw
2025-11-25
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Bydgoszcz, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan, Rzeszów
2025-10-03
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Gdansk, Katowice, Krakow, Opole
2025-10-03
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Bydgoszcz, Katowice, Krakow, Lublin, Nowy Targ, Olsztyn, Opole, Poznan
2025-10-01
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Opole, Gdansk
2025-09-26
Recruiting
Medical University of Silesia
Observational
300
Bialystok, Katowice, Kielce, Opole, Wroclaw
2025-09-15
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Skórzewo, Biała Podlaska, Warsaw, Opole, Lodz
2025-09-11
Recruiting
BeOne Medicines
Phase 3
351
Krakow, Opole, Warsaw
2025-08-27
Recruiting
American Heart of Poland
Not applicable
1,000
Chrzanów, Bielsko-Biala, Dąbrowa Górnicza, Ustroń, Katowice, Kędzierzyn-Koźle, Opole, Tychy
2025-08-25
Active, closed
A Study of SPY072 in Rheumatic Disease
NCT07148414Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
DrugSPY072
Spyre Therapeutics, Inc.
Phase 2
285
Krakow, Nowa Sól, Lodz, Warsaw, Opole, Gdynia, Warszawa, Elblag
2025-08-21
Recruiting
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06774131Upper Urinary Tract Urothelial Carcinoma, Urothelial Carcinoma
UroGen Pharma Ltd.
Phase 3
70
Opole, Gdansk, Bydgoszcz, Katowice, Lublin, Olsztyn, Szczecin, Wroclaw
2025-08-06
Recruiting
Pfizer
Phase 3
400
Bydgoszcz, Krakow, Wroclaw, Warsaw, Opole
2025-08-05
Recruiting
Celcuity Inc
Phase 3
1,180
Siedlce, Bydgoszcz, Konin, Krakow, Lodz, Opole, Szczecin, Warsaw
2025-07-24
Recruiting
Eli Lilly and Company
Phase 3
290
Lublin, Opole, Piotrkow Trybunalski, Poznan, Rzeszów, Szczecin, Warsaw, Wroclaw
2025-06-26
Recruiting
Eli Lilly and Company
Phase 3
350
Katowice, Opole, Piotrkow Trybunalski, Poznan, Rzeszów, Szczecin, Warsaw, Wroclaw
2025-06-26
Recruiting
Noradrenaline Versus Standard Blood Pressure Management for Perioperative Hypotension in Non-cardiac Surgery
NCT06885268Blood Pressure Management, Intraoperative Hypotension, Non-cardiac Surgery
Jagiellonian University
Phase 3
750
Katowice, Krakow, Olsztyn, Opole, Zabrze
2025-06-24
Recruiting
Immunovant Sciences GmbH
Phase 2
210
Bialystok, Szczecin, Bydgoszcz, Chorzów, Kielce, Lublin, Olsztyn, Opole
2025-06-19
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Bydgoszcz, Katowice, Krakow, Opole, Poznan, Rzeszów, Sopot, Staszów
2025-05-27
Active, closed
Celgene
Phase 3
960
Poznan, Wroclaw, Warsaw, Opole, Gdansk, Bytom, Bydgoszcz, Katowice
2025-03-13
Recruiting
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
NCT06688331Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1
DrugRituximab
PolTREG S.A.
Phase 2
150
Bialystok, Gdansk, Katowice, Lodz, Lublin, Opole, Rzeszów, Szczecin
2025-03-12
Recruiting
Alleviant ALLAY-HFrEF Study
NCT06812533Heart Failure
Alleviant Medical, Inc.
Not applicable
350
Opole, Warsaw, Wroclaw
2025-03-10
Active, closed
Takeda
Phase 3
1,583
Poznan, Krakow, Katowice, Sochaczew, Warsaw, Opole, Bialystok, Bytom
2025-03-03
Active, closed
Real-life Treatment Outcomes of Ravulizumab in PNH
NCT06633536Paroxysmal Nocturnal Haemoglobinuria
DrugRavulizumab
AstraZeneca
Observational
64
Bialystok, Brzozów, Bydgoszcz, Gdansk, Krakow, Lodz, Lublin, Opole
2025-02-06
Not yet open
Diluted and Undiluted Enteral Nutrition
NCT06516835Critical Illness, Surgery, Enteral Feeding Intolerance, Gastro-Intestinal Disorder
Medical University of Lublin
Not applicable
60
Gorzów Wielkopolski, Krakow, Lublin, Opole
2025-01-02
Recruiting
Cytokinetics
Phase 3
1,800
Warsaw, Bialystok, Krakow, Lodz, Miechów, Opole, Poznan, Ruda Śląska
2024-12-19
Recruiting
Sanofi
Phase 2
84
Poznan, Lodz, Opole
2024-12-19
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Bialystok, Biała Podlaska, Brzozów, Gdansk, Gliwice, Lodz, Olsztyn, Opole
2024-12-12
Recruiting
BeOne Medicines
Phase 1/2
80
Gdansk, Lublin, Olsztyn, Opole, Warsaw
2024-11-27
Recruiting
Osteogenon in Orthopedics and Traumatology
NCT07210281Patients With Fractures
University of Opole
Phase 4
150
Opole
2024-11-01
Recruiting
Abivax S.A.
Phase 2
212
Bydgoszcz, Kielce, Knurów, Krakow, Lodz, Nowy Targ, Opole, Piotrkow Trybunalski
2024-10-30
Recruiting
EXtensive mulTilayer stEnt treatmeNt in Aortic disSectiOn
NCT06675617Type B Aortic Dissection
Intressa Vascular SA
Not applicable
72
Bydgoszcz, Opole, Poznan, Rzeszów, Warsaw, Zielona Góra
2024-10-30
Recruiting
Pfizer
Phase 3
900
Krakow, Wroclaw, Lublin, Warsaw, Koszalin, Opole, Piotrkow Trybunalski
2024-10-22
Active, closed
Pfizer
Phase 3
609
Grudziądz, Torun, Krakow, Wroclaw, Opole, Koszalin
2024-10-21
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Bialystok, Biała Podlaska, Brzozów, Gdansk, Gliwice, Lodz, Olsztyn, Opole
2024-10-18
Active, closed
Eli Lilly and Company
Phase 2
143
Bydgoszcz, Krakow, Lodz, Lublin, Opole, Poznan, Sopot, Torun
2024-10-10
Recruiting
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
385
Bydgoszcz, Częstochowa, Elblag, Gdansk, Katowice, Krakow, Kłodzko, Opole
2024-07-18
Recruiting
Amgen
Phase 3
450
Gdynia, Kielce, Lodz, Opole, Poznan, Warsaw
2024-07-17
Active, closed
Windtree Therapeutics
Phase 1/2
20
Bialystok, Opole, Wroclaw
2024-06-01
Recruiting
Silesian Centre for Heart Diseases
Phase 4
600
Opole, Gliwice, Zabrze, Kielce
2024-04-17
Recruiting
Uniwersytecki Szpital Kliniczny w Opolu
Observational
50
Opole
2023-12-19
Active, closed
AnaptysBio, Inc.
Phase 2
420
Poznan, Torun, Nowa Sól, Warsaw, Opole, Bytom, Bialystok, Bydgoszcz
2023-08-31
Active, closed
Hoffmann-La Roche
Phase 3
459
Krakow, Lodz, Opole, Poznan, Warsaw
2023-08-08
Active, closed
Alfasigma S.p.A.
Phase 3
495
Bialystok, Elblag, Katowice, Lubin, Lublin, Nowa Sól, Olsztyn, Opole
2023-04-05
Recruiting
AstraZeneca
Phase 3
4,300
Bialystok, Grudziądz, Koszalin, Lodz, Lublin, Opole, Poznan, Racibórz
2023-03-31
Active, closed
Bristol-Myers Squibb
Phase 3
579
Bydgoszcz, Krakow, Opole, Poznan, Warsaw
2023-03-06
Recruiting
Alleviant ALLAY-HF Study
NCT05685303Heart Failure
Alleviant Medical, Inc.
Not applicable
700
Opole, Poznan, Wejherowo, Wroclaw, Zabrze
2023-01-10
Recruiting
Greenwich LifeSciences, Inc.
Phase 3
2,250
Gdansk, Konin, Krakow, Opole, Poznan, Rzeszów, Słupsk, Warsaw
2022-12-16
Active, closed
Celcuity Inc
Phase 3
701
Bydgoszcz, Konin, Krakow, Lodz, Opole, Siedlce, Szczecin, Warsaw
2022-12-08
Active, closed
AbbVie
Phase 1
283
Opole, Wroclaw, Lublin, Gdansk
2022-10-20
Active, closed
Eli Lilly and Company
Phase 3
8,000
Gdynia, Koszalin, Lodz, Opole, Oświęcim, Siedlce, Torun, Warsaw
2022-10-04
Active, closed
Exelixis
Phase 3
901
Bydgoszcz, Opole, Siedlce, Tomaszów Mazowiecki, Warsaw
2022-09-07
Active, closed
Gilead Sciences
Phase 3
443
Gdansk, Gliwice, Opole, Poznan, Siedlce, Warsaw
2022-07-25
Active, closed
Gilead Sciences
Phase 3
623
Gdansk, Gliwice, Opole, Siedlce, Warsaw
2022-07-20
Active, closed
Incyte Corporation
Phase 1/2
53
Skórzewo, Krakow, Wroclaw, Warsaw, Opole, Gdynia, Lodz, Olsztyn
2022-07-19
Active, closed
Hoffmann-La Roche
Phase 3
922
Gdansk, Konin, Koszalin, Opole, Pi?a, Późna, Rzeszów, Warsaw
2022-07-18
Active, closed
Eli Lilly and Company
Phase 3
925
Lublin, Opole, Gdynia, Lodz, Piotrkow Trybunalski
2022-04-14
Active, closed
AstraZeneca
Phase 3
1,035
Nowa Sól, Opole, Wieliszew
2022-03-25
Active, closed
Eli Lilly and Company
Phase 3
368
Otwock, Opole
2022-03-11
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Lodz, Gliwice, Gdansk, Opole
2022-03-07
Active, closed
AstraZeneca
Phase 3
363
Lodz, Olsztyn, Opole, Poznan, Rzeszów
2022-02-15
Recruiting
Heidelberg Pharma AG
Phase 1/2
78
Katowice, Krakow, Lodz, Opole, Skórzewo, Torun
2022-02-07
Not yet open
Medical University of Gdansk
Phase 2
126
Poznan, Wroclaw, Warsaw, Opole, Gdansk, Gliwice
2022-01-01
Active, closed
AstraZeneca
Phase 3
506
Gdansk, Krakow, Opole, Warsaw
2021-06-22
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Krakow, Wroclaw, Warsaw, Opole, Gdynia
2021-04-05
Active, closed
Sellas Life Sciences Group
Phase 3
127
Bydgoszcz, Gdansk, Gdynia, Kielce, Legnica, Olsztyn, Opole, Słomniki
2021-02-08
Active, closed
Daiichi Sankyo
Phase 3
1,600
Poznan, Opole, Gdansk, Lodz, Warsaw
2020-12-04
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Krakow, Wroclaw, Gdynia, Katowice, Lodz, Opole, Skorzewo, Warsaw
2020-09-16
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Bialystok, Gdansk, Katowice, Lodz, Opole, Warsaw
2019-08-15
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Bydgoszcz, Krakow, Opole, Olsztyn, Biała Podlaska, Gdansk, Lodz, Lublin
2019-08-09
Active, closed
Institut de Recherches Internationales Servier
Phase 3
856
Bialystok, Gdansk, Konin, Lodz, Olsztyn, Opole, Poznan, Tomaszów Mazowiecki
2019-03-21
Active, closed
Kartos Therapeutics, Inc.
Phase 2
20
Wroclaw, Opole
2019-01-15
Active, closed
AstraZeneca
Phase 1/2
243
Gdansk, Krakow, Lublin, Opole, Rzeszów, Warsaw
2018-12-21
Recruiting
Vanda Pharmaceuticals
Phase 1
42
Biała Podlaska, Katowice, Krakow, Opole, Skorzewo, Warsaw, Wroclaw
2018-09-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Konin, Poznan, Bydgoszcz, Krakow, Warsaw, Opole, Bialystok, Gdansk
2018-08-21
Active, closed
GlaxoSmithKline
Phase 2
237
Brzozów, Chorzów, Gdansk, Krakow, Lublin, Opole, Poznan
2018-05-03
Recruiting
Prevalence, Determinants and Natural History of Frailty and Pre-frailty in Elderly People
NCT04518423Frailty, Frailty Syndrome, Frail Elderly Syndrome, Fragility
The Opole University of Technology
Observational
1,093
Opole
2017-09-02
Active, closed
Eli Lilly and Company
Phase 3
5,637
Konin, Poznan, Wroclaw, Lublin, Warsaw, Opole, Gdansk, Gdynia
2017-07-12
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
5,796
Gdansk, Lodz, Opole, Warsaw
2015-08
Active, closed
Acerta Pharma BV
Phase 3
533
Bydgoszcz, Gdansk, Gdynia, Krakow, Lodz, Olsztyn, Opole, Słupsk
2015-07-28
Active, closed
Acerta Pharma BV
Phase 3
535
Bydgoszcz, Gdansk, Gdynia, Krakow, Lodz, Lublin, Olsztyn, Opole
2015-06-26
Active, closed
AstraZeneca
Phase 3
510
Brzozów, Bydgoszcz, Gdansk, Grudziądz, Krakow, Lubin, Olsztyn, Opole
2013-09-25
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Brzozów, Chorzów, Gdansk, Klinika Nowotworow Ukladu Chlonnego, Krakow, Opole, Słupsk, Wroclaw
2013-09-09
Rows per page Showing 1–106 of 106
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Polish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 November 2026. https://priyalifescience.com/clinical-trials-poland/city/opole

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Poland and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,716 studies in total at the last sync on 15 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 106 of those studies with a site in Opole.

How many clinical trials are recruiting in Opole?

62 of the 106 studies on this page are recruiting new participants as of the 15 Nov 2026, 03:18 UTC sync. A further 3 have not yet opened recruitment, 40 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Opole), 106 studies
PhaseStudiesRecruitingShare
Phase 3613157.5%
Phase 2201318.9%
Phase 2/3655.7%
Not applicable544.7%
Observational544.7%
Phase 1/2524.7%
Phase 1211.9%
Phase 4221.9%

Most active sponsors

Lead sponsors with the most studies (Opole)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC85
AstraZeneca71
Bristol-Myers Squibb76
Eli Lilly and Company72
Pfizer54
Hoffmann-La Roche42
BeOne Medicines33
Spyre Therapeutics, Inc.31
Takeda32
Acerta Pharma BV20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.